December 20, 2024
Due to the ongoing manufacturing shortage of UDENYCA®, Cigna HealthcareSM has extended the approval date for prescribing the alternative medication, NYVEPRIA™, through February 19, 2025. Approval for the alternative was scheduled to end on December 31, 2024.
NYVEPRIA is approved as an alternative medication when a prior authorization for UDENYCA is already on file for a patient with Cigna Healthcare coverage. We will continue to monitor the supply interruption.
As a reminder, providers are required to follow the standard prior authorization process to prescribe any other alternative medications.
Additional information
The following chart details the current status and Healthcare Common Procedure Coding System (HCPCS) codes for UDENYCA and alternative medications.
| Drug brand name | Generic drug name | HCPCS code | Current status |
| UDENYCA® | pegfilgrastim-cbqv | Q5111 | Supply interruption at the manufacturer |
| UDENYCA® Autoinjector | pegfilgrastim-cbqv | Q5111 | Supply interruption at the manufacturer |
| UDENYCA® ON-BODY Injector | pegfilgrastim-cbqv | Q5111 | Supply interruption at the manufacturer |
| NYVEPRIA™ | pegfilgrastim-apgf | Q5122 | Approved UDENYCA® alternative |
| Fulphila® | pegfilgrastim-jmdb | Q5108 | Standard prior authorization required |
| Fylnetra® | pegfilgrastim-pbbk | Q5130 | Standard prior authorization required |
| Neulasta® Onpro® | pegfilgrastim | J2506 | Standard prior authorization required |
| Neulasta® Injection | pegfilgrastim | J2506 | Standard prior authorization required |
| STIMUFEND® | pegfilgrastim-fpgk | Q5127 | Standard prior authorization required |
| Ziextenzo® | pegfilgrastim-bmez | Q5120 | Standard prior authorization required |
Please let us know what you think of the Provider Newsroom information and news.
Contact Us
